Cargando…
Canagliflozin, characterized as a HDAC6 inhibitor, inhibits gastric cancer metastasis
Gastric cancer is a common gastrointestinal cancer. Survival outcome for patients with the recurrence or metastasis remains poor due to the lack of effective targeting drugs. The mechanisms of non-histone acetylation modifications are key epigenetic regulations that participate in various biological...
Autores principales: | Jiang, Dandan, Ma, Peizhi |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9705739/ https://www.ncbi.nlm.nih.gov/pubmed/36457493 http://dx.doi.org/10.3389/fonc.2022.1057455 |
Ejemplares similares
-
The Lethality of [Pazopanib + HDAC Inhibitors] Is Enhanced by Neratinib
por: Booth, Laurence, et al.
Publicado: (2019) -
Identification of Clinically Approved Drugs Indacaterol and Canagliflozin for Repurposing to Treat Epidermal Growth Factor Tyrosine Kinase Inhibitor-Resistant Lung Cancer
por: Li, Hongjian, et al.
Publicado: (2017) -
Preclinical Evaluation of the HDAC Inhibitor Chidamide in Transformed Follicular Lymphoma
por: Zhong, Mengya, et al.
Publicado: (2021) -
Axitinib and HDAC Inhibitors Interact to Kill Sarcoma Cells
por: Roberts, Jane L., et al.
Publicado: (2021) -
Characterization of the Prognostic m6A-Related lncRNA Signature in Gastric Cancer
por: Wang, Haixu, et al.
Publicado: (2021)